Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.

Kularatne SA, Thomas M, Myers CH, Gagare P, Kanduluru AK, Crain CJ, Cichocki BN.

Clin Cancer Res. 2018 Sep 10. pii: clincanres.0803.2018. doi: 10.1158/1078-0432.CCR-18-0803. [Epub ahead of print]

PMID:
30201762
2.

Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts.

Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS.

Bioconjug Chem. 2018 Apr 18;29(4):1319-1326. doi: 10.1021/acs.bioconjchem.8b00063. Epub 2018 Feb 27.

PMID:
29466853
3.

New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange.

Rangasamy L, Chelvam V, Kanduluru AK, Srinivasarao M, Bandara NA, You F, Orellana EA, Kasinski AL, Low PS.

Bioconjug Chem. 2018 Apr 18;29(4):1047-1059. doi: 10.1021/acs.bioconjchem.7b00714. Epub 2018 Mar 2.

4.

Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers.

Kanduluru AK, Low PS.

Mol Pharm. 2017 Nov 6;14(11):3859-3865. doi: 10.1021/acs.molpharmaceut.7b00583. Epub 2017 Oct 17.

PMID:
28969417
5.

Antitumor agent 25-epi Ritterostatin GN1N induces endoplasmic reticulum stress and autophagy mediated cell death in melanoma cells.

Riaz Ahmed KB, Kanduluru AK, Feng L, Fuchs PL, Huang P.

Int J Oncol. 2017 May;50(5):1482-1490. doi: 10.3892/ijo.2017.3944. Epub 2017 Apr 3.

6.

Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers.

Kanduluru AK, Srinivasarao M, Low PS.

Bioconjug Chem. 2016 Sep 21;27(9):2157-65. doi: 10.1021/acs.bioconjchem.6b00374. Epub 2016 Sep 2.

7.

Substrate-Triggered Exosite Binding: Synergistic Dendrimer/Folic Acid Action for Achieving Specific, Tight-Binding to Folate Binding Protein.

Chen J, van Dongen MA, Merzel RL, Dougherty CA, Orr BG, Kanduluru AK, Low PS, Marsh EN, Banaszak Holl MM.

Biomacromolecules. 2016 Mar 14;17(3):922-7. doi: 10.1021/acs.biomac.5b01586. Epub 2016 Feb 3.

PMID:
26815158
8.

DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.

Roy J, Nguyen TX, Kanduluru AK, Venkatesh C, Lv W, Reddy PV, Low PS, Cushman M.

J Med Chem. 2015 Apr 9;58(7):3094-103. doi: 10.1021/jm5018384. Epub 2015 Mar 30.

PMID:
25822623
9.

Avidity mechanism of dendrimer-folic acid conjugates.

van Dongen MA, Silpe JE, Dougherty CA, Kanduluru AK, Choi SK, Orr BG, Low PS, Banaszak Holl MM.

Mol Pharm. 2014 May 5;11(5):1696-706. doi: 10.1021/mp5000967. Epub 2014 Apr 11.

10.

A convergent total synthesis of the potent cephalostatin/ritterazine hybrid -25-epi ritterostatin GN1N.

Kanduluru AK, Banerjee P, Beutler JA, Fuchs PL.

J Org Chem. 2013 Sep 20;78(18):9085-92. doi: 10.1021/jo401171q. Epub 2013 Aug 29.

PMID:
23899273
11.

Towards a KCC2 blocker pharmacophore model.

Lebon F, Pégurier C, Ledecq M, Mathieu B, Bosman N, Frycia A, Lengelé S, Dhurke K, Kanduluru AK, Meunier S, Wagner A, Wolff C, Provins L.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):3978-82. doi: 10.1016/j.bmcl.2012.04.097. Epub 2012 Apr 30.

PMID:
22608391
12.

Benzyl prolinate derivatives as novel selective KCC2 blockers.

Pégurier C, Bosman N, Collart P, Delporte ML, Leclercq K, Lengelé S, Kanduluru AK, Meunier S, Pacico N, Vadali LR, Wagner A, Wolff C, Provins L.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2542-5. doi: 10.1016/j.bmcl.2010.02.092. Epub 2010 Mar 1.

PMID:
20299216

Supplemental Content

Loading ...
Support Center